Evotec Se(OTC) EVOTF

Market Cap$1.19B

Since IPO (2004)+86%

5 Year-85%

1 Year-19%

1 Month+28%

$6.69

+0.00%

+0.00Today

Evotec Se last closing stock price
Metric	Price	Date
Last close	USD 6.69	2026-06-02

Evotec Se stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 6.69	2026-05-14
1 month	+27.67%	USD 5.24	2026-03-19
3 month	+7.73%	USD 6.21	2026-01-30
Year to date	-16.48%	USD 8.01	2025-12-26
1 year	-19.11%	USD 8.27	2025-05-30
3 year	-68.4%	USD 21.17	2023-05-30
5 year	-84.63%	USD 43.52	2021-06-03
Since inception	+85.83%	USD 3.60	2004-07-23

Evotec Se Financials at a Glance

Market Cap

$1.19B

Revenue (TTM)

€745.54M

Net Income (TTM)

-€194.35M

EPS (TTM)

-$1.27

P/E Ratio

-5.27

Dividend

$0.00

Beta (Volatility)

0.15 (Low)

Dividend

$0.00

Beta (Volatility)

0.15 (Low)

Price

$6.69

Volume

Open

$6.49

Price

$6.69

Volume

Open

$6.49

Previous Close

$6.69

Daily Range

$6.49 - $6.69

52-Week Range

$4.73 - $8.52

Estimated Earnings Date

Aug 13, 2026

Dividend

$0.00

Beta (Volatility)

0.15 (Low)

Price

$6.69

Volume

Open

$6.49

Previous Close

$6.69

Daily Range

$6.49 - $6.69

52-Week Range

$4.73 - $8.52

Estimated Earnings Date

Aug 13, 2026

EVOTF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Evotec Se

Evotec SE is a leading global partner in drug discovery and development services, catering to the pharmaceutical and biotechnology sectors. The company focuses on advancing pharmaceutical products across various therapeutic areas, including oncology, CNS disorders, and infectious diseases.

Products and Services

Comprehensive drug discovery and development services
Collaboration agreements with major pharmaceutical companies
Focus on diverse therapeutic areas including oncology and immunology

Growth Outlook

Strong partnerships with industry leaders like Bayer and Pfizer
Expanding portfolio in high-demand therapeutic areas
Recent quarterly revenue growth indicates potential for future profitability

Financial Highlights

Recent quarterly revenue of €157.2 million
Trailing twelve months (TTM) revenue of €753.5 million
Current ratio of 1.68 suggests strong liquidity position

Evotec SE has established itself as a significant player in the healthcare sector, particularly in drug development. The company's extensive collaborations with leading pharmaceutical firms enhance its capabilities and market reach. Recent financial performance shows promising revenue growth, indicating a potential upward trajectory. The current ratio reflects a solid liquidity position, which is crucial for sustaining operations and funding future projects. Overall, Evotec SE presents an intriguing opportunity for investors interested in the biotechnology and pharmaceutical sectors.

AI Generated • Jul 29, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

4,526

CEO

Christian Wojczewski, PhD

Website

www.evotec.com

Headquarters

Hamburg, HA 22419, DE

EVOTF Financials

Key Financial Metrics (TTM)

Gross Margin

11.47%

Operating Margin

-13.88%

Net Income Margin

-26.02%

Return on Equity

-24.55%

Return on Capital

-11.17%

Return on Assets

-11.82%

Earnings Yield

-18.98%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.19B

Shares Outstanding

177.62M

Volume

Avg. Volume

3.365

Financials (TTM)

Gross Profit

€85.39M

Operating Income

-€103.65M

EBITDA

-€38.73M

Operating Cash Flow

€20.51M

Capital Expenditure

-€62.94M

Free Cash Flow

-€42.43M

Cash & ST Invst.

€446.45M

Total Debt

€388.93M

Evotec Se Performance Analysis

Evotec Se annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 789,752,548	8.1%
2023	2023-12-31	EUR 844,811,841	7.0%
2024	2024-12-31	EUR 862,071,837	2.0%
2025	2025-12-31	EUR 889,740,385	3.2%

Evotec Se sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-14.4%
Q3	2025-09-30	-4.3%
Q4	2025-12-31	54.5%
Q1	2026-03-31	-37.9%

Evotec Se annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR -1.04	N/A
2023	2023-12-31	EUR -0.51	-50.9%
2024	2024-12-31	EUR -1.20	133.3%
2025	2025-12-31	EUR -0.66	-45.0%

Evotec Se sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-33.3%
Q3	2025-09-30	N/A
Q4	2025-12-31	134.3%
Q1	2026-03-31	-938.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

€157.24M

-21.4%

Gross Profit

-€1.57M

-105.8%

Gross Margin

-1.00%

N/A

Market Cap

$1.19B

N/A

Market Cap/Employee

$249.32K

N/A

Employees

4,766

N/A

Net Income

-€122.40M

-287.6%

EBITDA

-€31.74M

-15.6%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

€446.45M

+17.9%

Total Debt

€388.93M

-18.8%

Accounts Receivable

€167.69M

-24.2%

Inventory

€33.11M

-1.2%

Long Term Debt

€299.98M

-33.6%

Short Term Debt

€88.95M

+46.0%

Return on Assets

-11.82%

N/A

Return on Invested Capital

-8.50%

N/A

Free Cash Flow

-€6.33M

+88.2%

Operating Cash Flow

-€2.15M

+93.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

LJUIFSSY Group Limited

LJUIFSSY Group Limited$0.40+0.00%

CMOPFCosmo Pharmaceuticals N.V.

CMOPFCosmo Pharmaceuticals N.V.$74.00-1.40%

TCNNFTrulieve Cannabis Corp.

TCNNFTrulieve Cannabis Corp.$8.10-2.76%

GNMLFGenomma Lab Internacional, S.A.B. de C.V.

GNMLFGenomma Lab Internacional, S.A.B. de C.V.$0.83+0.00%

NPPNYNippon Shinyaku Co., Ltd.

NPPNYNippon Shinyaku Co., Ltd.$6.11+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$200.75+0.03%

AAPLApple

AAPLApple$308.91-0.07%

AMZNAmazon

AMZNAmazon$271.58+0.15%

INTCIntel

INTCIntel$90.20-0.01%

FCUVFocus Universal

FCUVFocus Universal$11.60+5.17%

NOKNokia

NOKNokia$9.14+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.62+0.02%

Questions About EVOTF

What is the current price of Evotec Se?

Evotec Se is trading at $6.69 per share.

What is the 52-week range for Evotec Se?

Over the past 52 weeks, Evotec Se has traded between $4.73 and $8.52.

How much debt does Evotec Se have?

As of the most recent reporting period, Evotec Se reported total debt of €446.43M.

How much cash does Evotec Se have on hand?

Evotec Se reported €446.95M in cash and cash equivalents in its most recent financial results.

What is Evotec Se’s dividend yield?

Evotec Se does not currently have a dividend yield.

Evotec Se(OTC) EVOTF

Evotec Se Financials at a Glance

EVOTF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Evotec Se

EVOTF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Evotec Se Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About EVOTF

What is the current price of Evotec Se?

What is the 52-week range for Evotec Se?

How much debt does Evotec Se have?

How much cash does Evotec Se have on hand?

What is Evotec Se’s dividend yield?

Premium Investing Services